Cooley is growing its market-leading intellectual property litigation practice group with the addition of partners Sanya Sukduang and Jonathan Davies, who will be based in Washington, DC. Arriving from Finnegan, Henderson, Farabow, Garrett & Dunner, Sukduang’s and Davies’ practices focus on life sciences with an emphasis on pharmaceuticals litigation, including Hatch‐Waxman Abbreviated New Drug Application (ANDA) litigation.
“Sanya’s and Jonathan’s experience navigating complex ANDA cases adds significant depth to the life sciences component of our IP litigation practice and complements the work done by our patent counseling and life sciences partnering practice groups,” said Stephen Smith, chair of Cooley’s intellectual property litigation practice. “Together, their experience will prove an invaluable asset to our clients, particularly the increasing number of them with later-stage products ripe for ANDA litigation.”
Sukduang advises clients on patent litigation before federal district courts and the US Court of Appeals for the Federal Circuit, as well as all aspects of proceedings before the Patent Trial and Appeal Board. His work centers on litigating matters concerning ANDA challenges for brand drug manufacturers, diagnostic methods, biological products and medical devices. Sukduang also guides clients on an array of issues concerning biologics, including due diligence investigations and strategic patent portfolio planning. He formerly chaired Finnegan’s diversity and inclusion committee.
Davies’ practice centers around patent litigation, particularly on pharmaceutical and biotechnology cases, including Hatch‐Waxman litigation related to ANDAs and biologics litigation under the Biologics Price Competition and Innovation Act. He has deep experience advising on all aspects of pre‐trial and trial federal district court practice, in addition to advising clients on infringement and validity opinions. Prior to his legal career, Davies completed graduate studies in human physiology and conducted doctoral and post-doctoral research in cellular and molecular biology and genetics.
“We know firsthand how high stakes ANDA litigation is for the innovative companies we advise,” said Sukduang. “We are excited about the opportunities we’ll be able to provide our clients with the support of Cooley’s powerful IP litigation platform.”
“We look forward to delivering successful results for our clients as we team up with our new colleagues,” said Davies. “We are also impressed by Cooley’s standout, collaborative culture and are eager to help build on the firm’s legacy as it continues to grow.”
With a team of 60+ lawyers, Cooley’s IP litigation practice is renowned for its ability to win bet-the-company competitor cases in which multibillion-dollar products, technologies and brands are at stake. The practice has unprecedented experience representing clients in tech and life sciences matters. Cooley boasts one of the most active patent litigation practices in the US, having handled 525+ patent cases and 70+ Federal Circuit patent appeals, the vast majority as the appellee, in the past five years.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.
Source: www.cooley.com
